Merck

Merck Predicts Over 80 Potential Oncology Approvals Through 2028
BioSpace
Wed, 06/8/22 - 10:32 am
Merck
oncology
ASCO 2022
Keytruda
#ASCO2022 roundup: CG Oncology builds on head-turning combo data; EQRx doesn’t have a way into US markets
Endpoints
Mon, 06/6/22 - 10:31 am
ASCO 2022
CG Oncology
Merck
Keytruda
EQRx
sugemalimab
Yumanity's end: J&J pays $26M for neuroscience assets as reverse merger erases biotech
Fierce Biotech
Mon, 06/6/22 - 10:29 am
Yumanity Therapeutics
JNJ
Kineta
Merck
M&A
ASCO: Merck touts Keytruda's 'convergent' benefits across postsurgery lung cancer patient groups
Fierce Pharma
Mon, 05/30/22 - 10:18 am
ASCO 2022
Merck
Keytruda
lung cancer
ASCO: Merck's Keytruda combo data could spark hope for lymphoma patients who lack options
Fierce Biotech
Fri, 05/27/22 - 10:17 am
ASCO 2022
Merck
Keytuda
Lynparza
Lenvima
Merck study results signal blood cancer potential for new type of immunotherapy
BioPharma Dive
Thu, 05/26/22 - 10:40 pm
Merck
Bristol Myers Squibb
cancer
cancer immunotherapy
favezelimab
Hodgkin's lymphoma
US sees spike in Paxlovid usage as Merck's molnupiravir and AstraZeneca's Evusheld are slower off the shelf
Endpoints
Wed, 05/25/22 - 11:47 pm
Pfizer
HHS
Paxlovid
Merck
molnupiravir
AstraZeneca
Evusheld
COVID-19
The patent winter is coming
EP Vantage
Wed, 05/25/22 - 10:41 am
patents
biosimilars
patent cliff
Keytruda
Opdivo
Eliquis
Darzalex
Revlimid
Humira
Stelara
AbbVie
Merck
Bristol Myers Squibb
JNJ
Merck snaps up cancer drug from China’s Kelun in $1.4bn deal
Pharmaforum
Wed, 05/18/22 - 11:53 pm
Merck
immuno-oncology
China
Sichuan Kelun Pharmaceutical
Pfizer, Merck, AstraZeneca led Big Pharma's growth in Q1 but they couldn't match mRNA hotshots
Fierce Pharma
Tue, 05/17/22 - 10:43 am
Big Pharma
earnings
Pfizer
Merck
AstraZeneca
COVID-19
Moderna Therapeutics
BioNTech
Big pharma’s biggest spenders revealed
EP Vantage
Tue, 05/17/22 - 10:29 am
R&D
licensing
M&A
COVID-19
Big Pharma
Bristol Myers Squibb
JNJ
AbbVie
Sanofi
Merck
Novartis
Pfizer
AstraZeneca
Roche
GSK
Eli Lilly
ICER says Pfizer's Paxlovid, Merck's molnupiravir both cost effective, but their benefits are far from equal
Fierce Pharma
Tue, 05/10/22 - 10:50 am
ICER
Pfizer
Paxlovid
Merck
Ridgeback Biotherapeutics
molnupiravir
COVID-19
In wake of Biogen's skirmish with the SEC, pharma giants are changing the way they do quarterly reports
Endpoints
Thu, 05/5/22 - 11:34 pm
Biogen
earnings
SEC
Eli Lilly
Merck
Bristol Myers Squibb
Pfizer
AbbVie
Merck makes $3.2bn from COVID-19 drug Lagevrio in Q1
Pharmaforum
Thu, 04/28/22 - 10:48 pm
Merck
earnings
COVID-19
Lagevrio
Could This FDA Approval Be a Boost for Merck?
Motley Fool
Thu, 04/28/22 - 11:04 am
Merck
Keytruda
FDA
endometrial cancer
Merck brings former executive back to lead ex-US pharmaceuticals business
BioPharma Dive
Thu, 04/21/22 - 10:31 am
Merck
Joseph Romanelli
Merck wins breakthrough therapy designation for potential pneumococcal vaccine successor
Endpoints
Thu, 04/14/22 - 10:43 am
Merck
vaccines
pneumococcal disease
V116
FDA
The never-ending Zostavax story – in court. Merck gets a win, but thousands more lawsuits pending
Endpoints
Wed, 04/13/22 - 05:15 pm
Merck
legal
vaccines
Zostavax
shingles
Merck opens Virginia plant to support UNICEF deal for HPV vaccines
Endpoints
Thu, 04/7/22 - 05:58 pm
Merck
Virginia
drug manufacturing
UNICEF
vaccines
Gardasil 9
HPV
Merck looks to cardiovascular pipeline for $10B+ peak sales—and diversification from Keytruda
Fierce Biotech
Tue, 04/5/22 - 11:36 pm
Merck
Keytruda
cardiovascular disease

Pages